Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.

Cell proliferation - 1 Sept 2022

Dong Yiting, Zhao Lele, Duan Jianchun, Bai Hua, Chen Dongsheng, Li Si, Yu Yangyang, Xiao Mingzhe, Zhang Qin, Duan Qianqian, Sun Tingting, Qi Chuang, Wang Jie, Wang Zhijie

Abstract excerpt

BACKGROUND: Pappalysin 2 (PAPPA2) mutation, occurring most frequently in skin cutaneous melanoma (SKCM) and non-small cell lung cancer (NSCLC), is found to be related to anti-tumour immune response. However, the association between PAPPA2 and the efficacy of immune checkpoint inhibitors (ICIs) therapy remains unknown. METHODS: To analyse the performance of PAPPA2 mutation as an indicator stratifying beneficiaries...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35811392
DOI: 10.1111/cpr.13283
PMCID: PMC9436912

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.PMID 35811392Read ↗

Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics AnalysisSemantic proximity Read ↗

Prognostic value and immune status of AIM2 in skin cutaneous melanomaSemantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Illuminating HLA-DPA1 and HSH2D as Potential Prognostic Biomarkers by Weighted Gene Co-Expression Network Analysis for NRAS-Mutant Skin Cutaneous MelanomaSemantic proximity Read ↗

Mining novel biomarkers for prognosis of skin cutaneous melanoma with proteomic analysisSemantic proximity Read ↗

Construction of a tumor mutational burden-derived LncRNA prognostic computational framework associated with therapy sensitivity in skin cutaneous melanoma.Semantic proximity Read ↗

Ferroptosis-Related lncRNA Signature Predicts Prognosis and Immunotherapy Efficacy in Cutaneous MelanomaSemantic proximity Read ↗

Association Between FSIP2 Mutation and an Improved Prognosis in Patients With Skin Cutaneous Melanoma Treated With Immune Checkpoint InhibitorsSemantic proximity Read ↗

Molecular classification and subtype-specific characterization of skin cutaneous melanoma by aggregating multiple genomic platform data.Semantic proximity Read ↗

Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.Semantic proximity Read ↗

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung CancerSemantic proximity Read ↗

Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.